This sequence was first affirmed at the IARC Meeting 57 on July 7th 2020, where it was noted:

“The sequence was seen in 4.53% of all unmutated rearrangements, with 16,227 sequences including 5410 perfect alignments to the inferred allele. There was abundant variation in the CDR3 regions of the aligned sequences. A second IGLV3-25 allele, IGLV3-25*02, was also present in the genotype, at a lower frequency, and the inferred allele accounted for 73% of all IGLV3-25 alignments. Haplotype data is unavailable. Plots of the final 3’ nucleotides were considered, but the variability seen made it impossible to consider the final two nucleotides of the sequence. These were not part of the Genbank submission. The sequence has previously been reported as IGLV3-25*p04. The sequence, up to and including nucleotide 339, was affirmed as the Level 1 sequence, IGLV3-25*i01. It appears to represent the full length version of the previously truncated IGLV3-25*03 sequence. It was subsequently noted that since the submission of this sequence, an identical genomic sequence has been accepted by IMGT as the full length sequence IGLV3-25*03. The sequence, up to and including nucleotide 339 will be submitted to IMGT as IGLV3-25*i01 as a record of the rearrangability (and therefore likely functionality) of the sequence. “